Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: A randomized, double-blind study

European Journal of Cardiovascular Prevention & Rehabilitation

Volumn 8, Issue 6, 2001, Pages 383-390

  Paoletti, Rodolfo ^a   Fahmy, Maurice ^b   Mahla, Gerhard ^c   Mizan, Jacques ^d   Southworth, Harry ^d  

^a UNIVERSITY OF MILAN   (Italy)

^b Southlea Surgery   (United Kingdom)

^c NONE   (Germany)

^d ASTRAZENECA   (United Kingdom)

Author keywords

European Atherosclerosis Society guidelines; low density lipoprotein cholesterol; National Cholesterol Education Program guidelines; Rosuvastatin

Indexed keywords

ALANINE AMINOTRANSFERASE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PRAVASTATIN; PYRIMIDINES; SIMVASTATIN; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84992920491     PISSN: 17418267     EISSN: 17418275     Source Type: Journal    
DOI: 10.1177/174182670100800608     Document Type: Article

References (20)

1. Blumenthal RS. Statins: Effective antiatherosclerotic therapy. Am Heart J 2000; 139: 577–583.
2. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101: 207–213.
3. Scandinavian Simvastatin Survival StudyGroup. Randomised trial of cholesterol lowering in 4444 patients withcoronary heart disease: The Scandinavian Simvastatin Survival Study(4S). Lancet 1994; 344: 1383–1389.
4. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al For the Cholesterol and Recurrent Events Trial Investigators. Theeffect of pravastatin on coronary events after myocardial infarction inpatients with average cholesterol levels. N Engl JMed 1996; 335: 1001–1009.
5. Long-Term Intervention with Pravastatin inIschaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin inpatients with coronary heart disease and a broad range of initialcholesterol levels. N Engl J Med 1998; 339: 1349–1357.
6. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al For the West of Scotland Coronary Prevention Study Group.Prevention of coronary heart disease with pravastatin in men withhypercholesterolemia. N Engl J Med 1995; 333: 1301–1307.
7. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al For the AFCAPS/TexCAPS Research Group. Primaryprevention of acute coronary events with lovastatin in men and women withaverage cholesterol levels. Results ofAFCAPS/TexCAPS. JAMA 1998; 279: 1615–1622.
8. Knopp RH. Drug treatment of lipid disorders. N EnglJ Med 1999; 341: 498–511.
9. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versussimvastatin, pravastatin, lovastatin, and fluvastatin in patients withhypercholesterolemia (the CURVES study). Am JCardiol 1998; 81: 582–587.
10. Koren MJ, Smith DG, Hunninghake DB, Davidson MH, McKenney JM, Weiss SR, et al The cost of reaching National Cholesterol Education Program(NCEP) goals in hypercholesterolemic patients: A comparison of atorvastatin,simvastatin, lovastatin and fluvastatin. Pharmacoeconomics 1998; 14: 59–70.
11. Smith G, Davidson R, Bloor S, Burns K, Calnan C, McAulay P, et al Pharmacological properties of ZD4522—a new HMG-CoAreductase inhibitor [Abstract]. Atherosclerosis 2000; 151: 39. AbstractMoP20:W6.
12. Warwick AS, Dane AL, Raza A, Schneck DW. Single- and multiple-dose pharmacokinetics and safety of the newHMG-CoA reductase inhibitor ZD4522 [Abstract]. Atherosclerosis 2000; 151: 39. AbstractMoP19:W6.
13. Olsson AG, Pears JS, McKellar J, Caplan RJ, Raza A. Pharmacodynamics of new HMG-CoA reductase inhibitor ZD4522 in patientswith primary hypercholesterolaemia. Paper presented at the XIIthInternational Symposium on Atherosclerosis. Stockholm, Sweden, 28 June 2000.
14. Davidson MH, Ma PTS, Stein E, Hutchinson HG, Chitra R, Raza A, et al ZD4522 is superior to atorvastatin in decreasing low-densitylipoprotein cholesterol and increasing high-density lipoprotein cholesterolin patients with Type IIA or IIb hypercholesterolemia[Abstract]. J Am Coll Cardiol 2001; 37 (Suppl AAbstract):1261–1275.
15. Summary of the second report of theNational Cholesterol Education Program (NCEP) Expert Panel on Detection,Evaluation and Treatment of High Blood Cholesterol in Adults (AdultTreatment Panel II). JAMA 1993; 269: 3015–3023.
16. Prevention of coronary heart disease inclinical practice. Recommendations of the Second Joint Task Force of European andother Societies on Coronary Prevention. Eur Heart J 1998; 19: 1434–1503.
17. Peters JR, Quiter ES, Brekke ML, Admire J, Brekke MJ, Mullis RM, et al The Eating Pattern Assessment Tool: A simple instrument forassessing dietary fat and cholesterol intake. J AmDiet Assoc 1994; 94: 1008–1013.
18. Executive summary of the third report ofthe National Cholesterol Education Program (NCEP) Expert Panel on Detection,Evaluation, and Treatment of High Blood Cholesterol in Adults (AdultTreatment Panel III). JAMA 2001; 285: 2486–2497.
19. Bertolini S, Bon GB, Campbell LM, Farnier M, Langan J, Mahla G, et al Efficacy and safety of atorvastatin compared to pravastatin inpatients with hypercholesterolemia. Atherosclerosis 1997; 130: 191–197.
20. Gotto AM Jr, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S, et al Relation between baseline and on-treatment lipid parameters andfirst acute major coronary events in the Air Force/Texas CoronaryAtherosclerosis Prevention Study(AFCAPS/TexCAPS). Circulation 2000; 101: 477–484.